eviSIMILARs
Recombinant antibody reference materials for therapeutic R&D, assay development, and analytical applications.
Receive your quote directly from the manufacturer.
eviSIMILARs are reference antibodies designed for a broad range of assay and research applications. The selection includes multiple antibody formats, isotypes, fragment crystallizable (Fc) properties, and effector functions to support application-specific matching.
Reference antibody selection
The portfolio includes cetuximab, ipilimumab, pertuzumab, rituximab, trastuzumab, bevacizumab, adalimumab, alemtuzumab, panitumumab, eculizumab, omalizumab, and muromonab, also known as anti-cluster of differentiation 3 (anti-CD3) or OKT3.
Formats and Fc biology
eviSIMILARs are available as chimeric, humanized, human, and murine antibodies. These molecules span different isotypes and Fc characteristics, which can influence Fc biology and effector functions within an assay.
Key features and benefits of eviSIMILARs
- Comprehensive selection for diverse assay and research applications
- Includes 12 named reference antibodies
- Available in chimeric, humanized, human, and murine formats
- Offers varied isotypes, Fc properties, and effector functions
- Supports selection by required isotype and Fc characteristics rather than target alone
Product Overview
Links
Featured products
Request Quote for All Products
eviCONTROLs
evitriaevitria supplies recombinant isotype controls matched to your test antibody in subclass, format and production system. Expressed in our CHO transient platform under identical conditions, they let you separate genuine target engagement from non-specific binding and Fc-mediated background.